- Coordinator
- Fraunhofer Gesellschaft Zur Forderung Der Angewandten Forschung eV, Germany
- Runs
- 1 January 2024 to 30 June 2028
- Status
- Running
- EU funding
- €7.5m
- Total cost
- €7.5m
- Partners
- 21 organisations in 8 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101137192
What the project is doing
In the project's own words, from its summary on CORDIS.
The European Consortium ""Antiviral Therapeutics for Rapid Response Against Pandemic Infectious Diseases"" (AVITHRAPID) aims to support the search for novel broad-spectrum antiviral compounds by advancing multiple approaches. Building on a pre-existing set of bioactive small molecules, which are at least at the validated hit level, AVITHRAPID strives for the development of pre-clinical candidates targeting several viruses.
This will be achieved by combining the relevant expertisefor pre-clinical drug discovery, including molecular modeling, biochemical and cell-based assays, X-ray crystallography, medicinal chemistry, biophysical binding studies, ADMETox profiling, in vitro and in vivo PK, as well as animal disease models. In addition, the consortium aims to conduct a Phase 2a clinical trial for a small molecule developed against Zika virus.
Moreover, the consortium aims to identify and validate further viral targets and thereby contribute to the search for novel antiviral targets. As a consequence of the activities in AVITHRAPID, an early-stage drug discovery pipeline will be established that can be used to rapidly identify and develop novel antiviral compounds against emerging diseases.""
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Fraunhofer Gesellschaft Zur Forderung Der Angewandten Forschung eV | Munchen | Germany | Coordinator |
| Chelonia SA | Lugano | Switzerland | Associatedpartner |
| Schweizerisches Tropen Und Public Health Institut | Allschwil | Switzerland | Associatedpartner |
| Vsb - Technical University of Ostrava | Ostrava Poruba | Czechia | Participant |
| Helmholtz-Zentrum Fur Infektionsforschung GmbH | Braunschweig | Germany | Participant |
| Institut National De La Sante Et De La Recherche Medicale | Paris | France | Third party |
| Institut National De Recherche Pour L'agriculture, L'alimentation Et L'environnement | Paris | France | Participant |
| Universite De Tours | Tours | France | Participant |
| Dompe Farmaceutici SpA | Milano | Italy | Participant |
| Elettra - Sincrotrone Trieste Scpa | Basovizza Trieste | Italy | Participant |
| Euresist Network Geie | Roma Rm | Italy | Participant |
| Istituto Nazionale per Le Malattie Infettive Lazzaro Spallanzani-Istituto Di Ricovero E Cura a Carattere Scientifico | Roma | Italy | Participant |
| Universita Degli Studi Della Tuscia | Viterbo | Italy | Participant |
| Universita Degli Studi Di Cagliari | Cagliari | Italy | Participant |
| Universita Degli Studi Di Napoli Federico Ii | Napoli | Italy | Participant |
| Universita Degli Studi Di Perugia | Perugia | Italy | Participant |
| Universita Degli Studi Di Roma Tor Vergata | Roma | Italy | Participant |
| Universita Degli Studi Di Siena | Siena | Italy | Participant |
| Valsts zinatniskais instituts ""Nacionalais petniecibas un inovaciju instituts"""" | Riga | Latvia | Participant |
| First Health Pahrmaceuticals BV | Amsterdam | Netherlands | Participant |
| Fundacao Gimm - Gulbenkian Institute for Molecular Medicine | Lisboa | Portugal | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI